We have updated the Onselex Pharmaceuticals corporate presentation, including a supplemental IPO Roadmap at the end of the deck.

The main presentation highlights ONX-1006:

• Strong preclinical efficacy — Slide 5
• Favorable preclinical safety profile supported by NOAEL findings — Slide 6
• Sustained and extended dosing potential — Slide 7

Our near-term objective remains advancing ONX-1006 from a robust preclinical development package into human clinical evaluation for Stage IV pancreatic cancer.

The IPO Roadmap is illustrative and subject to financing, regulatory progress, clinical execution, and market conditions.